Structure and function of aggrecan

Cell Research

Volumn 12, Issue 1, 2002, Pages 19-32

  Kiani, Chris ^b   Chen, Liwen ^b   Wu, Yao Jiong ^b   Yee, Albert J ^b   Yang, Burton B ^a  

^a Orthopaedic and Arthritic Institute   (Canada)

^b NONE

Author keywords

Chondroitin sulfate; G1 domain; G3 domain; Glycosaminoglycan; Proteoglycan

Indexed keywords

ANIMALIA;

EID: 0002918488     PISSN: 10010602     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cr.7290106     Document Type: Review

References (84)

1. Hardingham TE, Fosang AJ. The structure of aggrecan and its turnover in cartilage. J Rheumatol Suppl 1995; 43:86-90.
2. Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, Heinegard D, Saxne T. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95(3):1071-7.
3. Wight TN, Kinsella MG, Qwarnstrom EE. The role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol 1992; 4(5):793-801.
4. Sajdera SW, Hascall VC. Proteinpolysaccharide complex from bovine nasal cartilage. A comparison of low and high shear extraction procedures. J Biol Chem 1969; 244(1):77-87.
5. Hardingham TE, Muir H. The specific interaction of hyaluronic acid with cartillage proteoglycans. Biochim Biophys Acta 1972; 279(2):401-5.
6. Hardingham TE, Muir H. Binding of oligosaccharides of hyaluronic acid to proteoglycans. Biochem J 1973; 135(4):905-8.
7. Heinegard D, Hascall VC. Aggregation of cartilage proteoglycans. 3. Characteristics of the proteins isolated from trypsin digests of aggregates. J Biol Chem 1974; 249(13):4250-6.
8. Zimmermann DR, Ruoslahti E. Multiple domains of the large fibroblast proteoglycan, versican. Embo J 1989; 8(10):2975-81.
9. Shinomura T, Nishida Y, Ito K, Kimata K. cDNA cloning of PG-M, a large chondroitin sulfate proteoglycan expressed during chondrogenesis in chick limb buds. Alternative spliced multiforms of PG-M and their relationships to versican. J Biol Chem 1993; 268(19):14461-9.
10. Yamada H, Watanabe K, Shimonaka M, Yamaguchi Y. Molecular cloning of brevican, a novel brain proteoglycan of the aggrecan/versican family. J Biol Chem 1994; 269(13):10119-26.
11. Goldstein LA, Zhou DF, Picker LJ, Minty CN, Bargatze RF, Ding JF, Butcher EC. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 1989; 56(6):1063-72.
12. Perkins SJ, Nealis AS, Dudhia J, Hardingham TE. Immunoglobulin fold and tandem repeat structures in proteoglycan N-terminal domains and link protein. J Mol Biol 1989; 206(4):737-53.
13. Mow VC, Zhu W, Lai WM, Hardingham TE, Hughes C, Muir H. The influence of link protein stabilization on the viscometric properties of proteoglycan aggregate solutions. Biochim Biophys Acta 1989; 992(2):201-8.
14. Watanabe H, Gao L, Sugiyama S, Doege K, Kimata K, Yamada Y. Mouse aggrecan, a large cartilage proteoglycan: protein sequence, gene structure and promoter sequence. Biochem J 1995; 308(Pt 2):433-40.
15. Doege KJ, Sasaki M, Kimura T, Yamada Y. Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan. Human-specific repeats, and additional alternatively spliced forms. J Biol Chem 1991; 266(2):894-902.
16. Yang BB, Zhang Y, Cao L, Yang BL. Aggrecan and link protein affect cell adhesion to culture plates and to type II collagen. Matrix Biol 1998; 16(9):541-61.
17. Lee V, Cao L, Zhang Y, Kiani C, Adams ME, Yang BB. The roles of matrix molecules in mediating chondrocyte aggregation, attachment, and spreading. J Cell Biochem 2000; 79(2):322-33.
18. Ang LC, Zhang Y, Cao L, Yang BL, Young B, Kiani C, Lee V, Allan K, Yang BB. Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol 1999; 58(6):597-605.
19. Zhang Y, Cao L, Yang BL, Yang BB. The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs. J Biol Chem 1998; 273(33):21342-51.
20. Zhang Y, Cao L, Kiani CG, Yang BL, Yang BB. The G3 domain of versican inhibits mesenchymal chondrogenesis via the epidermal growth factor-like motifs. J Biol Chem 1998; 273(49):33054-63.
21. Zhang Y, Wu Y, Cao L, Lee V, Chen L, Lin Z, Kiani C, Adams ME, Yang BB. Versican modulates embryonic chondrocyte morphology via the epidermal growth factor-like motifs in G3. Exp Cell Res 2001; 263(1):33-42.
22. Grover J, Roughley PJ. The expression of functional link protein in a baculovirus system: analysis of mutants lacking the A, B and B' domains. Biochem J 1994; 300(Pt 2):317-24.
23. Watanabe H, Yamada Y, Kimata K. Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function. J Biochem (Tokyo) 1998; 124(4):687-93.
24. Cao L, Zhang Y, Yang BB. Expression of the G1 domain of aggrecan interferes with chondrocyte attachment and adhesion. Matrix Biol 1998; 17(5):379-92.
25. Cao L, Yang BB. Chondrocyte apoptosis induced by aggrecan G1 domain as a result of decreased cell adhesion. Exp Cell Res 1999; 246(2):527-37.
26. Yang BL, Zhang Y, Cao L, Yang BB. Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem 1999; 72(2):210-20.
27. Kiani C, Lee V, Cao L, Chen L, Wu Y, Zhang Y, Adams ME, Yang BB. Roles of aggrecan domains in biosynthesis, modification by glycosaminoglycans and product secretion. Biochem J 2001; 354(Pt 1):199-207.
28. Yang BL, Cao L, Kiani C, Lee V, Zhang Y, Adams ME, Yang BB. Tandem repeats are involved in G1 domain inhibition of versican expression and secretion and the G3 domain enhances glycosaminoglycan modification and product secretion via the complement-binding protein-like motif. J Biol Chem 2000; 275(28):21255-61.
29. Mort JS, Buttle DJ. Cathepsin B. Int J Biochem Cell Biol 1997; 29(5): 715-20.
30. Mort JS, Magny MC, Lee ER. Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. Biochem J 1998; 335(Pt 3)(46):491-4.
31. Paulsson M, Morgelin M, Wiedemann H, Beardmore-Gray M, Dunham D, Hardingham T, Heinegard D, Timpl R, Engel J. Extended and globular protein domains in cartilage proteoglycans. Biochem J 1987; 245(3):763-72.
32. Dennis JE, Carrino DA, Schwartz NB, Caplan AI. Ultrastructural characterization of embryonic chick cartilage proteoglycan core protein and the mapping of a monoclonal antibody epitope. J Biol Chem 1990; 265(20):12098-103.
33. Barry FP, Neame PJ, Sasse J, Pearson D. Length variation in the keratan sulfate domain of mammalian aggrecan. Matrix Biol 1994; 14(4):323-8.
34. Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 1992; 267(27):19470-4.
35. Saxne T, Heinegard D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. Arthritis Rheum 1992; 35(4):385-90.
36. Morales TI, Hascall VC. Correlated metabolism of proteoglycans and hyaluronic acid in bovine cartilage organ cultures. J Biol Chem 1988; 263(8):3632-8.
37. Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, Caterson B. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem J 1999; 344 Pt 1:61-8.
38. Singer, II, Kawka DW, Bayne EK, Donatelli SA, Weidner JR, Williams HR, Ayala JM, Mumford RA, Lark MW, Glant TT, et al. VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. J Clin Invest 1995; 95(5):2178-86.
39. Fosang AJ, Last K, Maciewicz RA. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 1996; 98(10):2292-9.
40. Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, Singer, II, Donatelli SA, Weidner JR, Williams HR, Mumford RA, Lohmander LS. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997; 100(1):93-106.
41. Arner EC. Effect of animal age and chronicity of interleukin-1 exposure on cartilage proteoglycan depletion in vivo. J Orthop Res 1994; 12(3):321-30.
42. Lewthwaite J, Blake SM, Hardingham TE, Warden PJ, Henderson B. The effect of recombinant human interleukin 1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit. J Rheumatol 1994; 21(3):467-72.
43. Cawston T. Blocking cartilage destruction with metalloproteinase inhibitors: a valid therapeutic target? Ann Rheum Dis 1993; 52(11):769-70.
44. Buttle DJ, Handley CJ, Ilic MZ, Saklatvala J, Murata M, Barrett AJ. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthritis Rheum 1993; 36(12):1709-17.
45. Seed MP, Ismaiel S, Cheung CY, Thomson TA, Gardner CR, Atkins RM, Elson CJ. Inhibition of interleukin 1 beta induced rat and human cartilage degradation in vitro by the metalloproteinase inhibitor U27391. Ann Rheum Dis 1993; 52(1):37-43.
46. Larsson E, Mussener A, Heinegard D, Klareskog L, Saxne T. Increased serum levels of cartilage oligomeric matrix protein and bone sialoprotein in rats with collagen arthritis. Br J Rheumatol 1997; 36(12):1258-61.
47. Sandy JD, Flannery CR, Neame PJ, Lohmander LS. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest 1992; 89(5):1512-6.
48. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Nagase H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman MC, Jr., Hollis GF, Arner EC, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999; 284(5420):1664-6.
49. Lark MW, Williams H, Hoernner LA, Weidner J, Ayala JM, Harper CF, Christen A, Olszewski J, Konteatis Z, Webber R, et al. Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum. Biochem J 1995; 307(Pt 1)(4):245-52.
50. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993; 36(2):181-9.
51. Hughes CE, Caterson B, Fosang AJ, Roughley PJ, Mort JS. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. Biochem J 1995; 305(Pt 3):799-804.
52. Lark MW, Gordy JT, Weidner JR, Ayala J, Kimura JH, Williams HR, Mumford RA, Flannery CR, Carlson SS, Iwata M, et al. Cell-mediated catabolism of aggrecan. Evidence that cleavage at the And quot;aggrecanase and quot; site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain. J Biol Chem 1995; 270(6):2550-6.
53. Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest 1994; 94(1):25-33.
54. Poole AR. Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now? Ann Rheum Dis 1994; 53(1):3-5.
55. Ratcliffe A, Doherty M, Maini RN, Hardingham TE. Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann Rheum Dis 1988; 47(10):826-32.
56. Fosang AJ, Hardingham TE. Isolation of the N-terminal globular protein domains from cartilage proteoglycans. Identification of G2 domain and its lack of interaction with hyaluronate and link protein. Biochem J 1989; 261(3):801-9.
57. Watanabe H, Cheung SC, Itano N, Kimata K, Yamada Y. Identification of hyaluronan-binding domains of aggrecan. J Biol Chem 1997; 272(44):28057-65.
58. Fosang AJ, Hardingham TE. 1-C-6 epitope in cartilage proteoglycan G2 domain is masked by keratan sulphate. Biochem J 1991; 273(Pt 2):369-73.
59. Antonsson P, Heinegard D, Oldberg A. The keratan sulfate-enriched region of bovine cartilage proteoglycan consists of a consecutively repeated hexapeptide motif. J Biol Chem 1989; 264(27):16170-3.
60. Hopwood JJ, Robinson HC. The alkali-labile linkage between keratan sulphate and protein. Biochem J 1974; 141(1):57-69.
61. Hascall VC, Riolo RL. Characteristics of the protein-keratan sulfate core and of keratan sulfate prepared from bovine nasal cartilage proteoglycan. J Biol Chem 1972; 247(14):4529-38.
62. Nieduszynski IA, Huckerby TN, Dickenson JM, Brown GM, Tai GH, Morris HG, Eady S. There are two major types of skeletal keratan sulphates. Biochem J 1990; 271(1):243-5.
63. Krueger RC, Jr., Fields TA, Hildreth Jt, Schwartz NB. Chick cartilage chondroitin sulfate proteoglycan core protein. I. Generation and characterization of peptides and specificity for glycosaminoglycan attachment. J Biol Chem 1990; 265(20):12075-87.
64. McNicol D, Roughley PJ. Extraction and characterization of proteoglycan from human meniscus. Biochem J 1980; 185(3):705-13.
65. Bourdon MA, Krusius T, Campbell S, Schwartz NB, Ruoslahti E. Identification and synthesis of a recognition signal for the attachment of glycosaminoglycans to proteins. Proc Natl Acad Sci USA 1987; 84(10):3194-8.
66. Brennan MJ, Oldberg A, Pierschbacher MD, Ruoslahti E. Chondroitin/dermatan sulfate proteoglycan in human fetal membranes. Demonstration of an antigenically similar proteoglycan in fibroblasts. J Biol Chem 1984; 259(22):13742-50.
67. Chopra RK, Pearson CH, Pringle GA, Fackre DS, Scott PG. Dermatan sulphate is located on serine-4 of bovine skin proteodermatan sulphate. Demonstration that most molecules possess only one glycosaminoglycan chain and comparison of amino acid sequences around glycosylation sites in different proteoglycans. Biochem J 1985; 232(1):277-9.
68. Oldberg A, Hayman EG, Ruoslahti E. Isolation of a chondroitin sulfate proteoglycan from a rat yolk sac tumor and immunochemical demonstration of its cell surface localization. J Biol Chem 1981; 256(21):10847-52.
69. Bourdon MA, Oldberg A, Pierschbacher M, Ruoslahti E. Molecular cloning and sequence analysis of a chondroitin sulfate proteoglycan cDNA. Proc Natl Acad Sci USA 1985; 82(5): 1321-5.
70. Sant AJ, Cullen SE, Giacoletto KS, Schwartz BD. Invariant chain is the core protein of the Ia-associated chondroitin sulfate proteoglycan. J Exp Med 1985; 162(6):1916-34.
71. Upholt WB, Chandrasekaran L, Tanzer ML. Molecular cloning and analysis of the protein modules of aggrecans. Exs 1994; 70(4):37-52.
72. McCormick D, van der Rest M, Goodship J, Lozano G, Ninomiya Y, Olsen BR. Structure of the glycosaminoglycan domain in the type IX collagen-proteoglycan. Proc Natl Acad Sci USA 1987; 84(12):4044-8.
73. Fulop C, Walcz E, Valyon M, Glant TT. Expression of alternatively spliced epidermal growth factor-like domains in aggrecans of different species. Evidence for a novel module. J Biol Chem 1993; 268(23):17377-83.
74. Halberg DF, Proulx G, Doege K, Yamada Y, Drickamer K. A segment of the cartilage proteoglycan core protein has lectin-like activity. J Biol Chem 1988; 263(19):9486-90.
75. Ujita M, Shinomura T, Ito K, Kitagawa Y, Kimata K. Expression and binding activity of the carboxyl-terminal portion of the core protein of PG-M, a large chondroitin sulfate proteoglycan. J Biol Chem 1994; 269(44):27603-9.
76. Aspberg A, Binkert C, Ruoslahti E. The versican C-type lectin domain recognizes the adhesion protein tenascin-R. Proc Natl Acad Sci USA 1995; 92(23):10590-4.
77. Aspberg A, Miura R, Bourdoulous S, Shimonaka M, Heinegard D, Schachner M, Ruoslahti E, Yamaguchi Y. The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety. Proc Natl Acad Sci USA 1997; 94(19):10116-21.
78. Li H, Schwartz NB, Vertel BM. cDNA cloning of chick cartilage chondroitin sulfate (aggrecan) core protein and identification of a stop codon in the aggrecan gene associated with the chondrodystrophy, nanomelia. J Biol Chem 1993; 268(31):23504-11.
79. Watanabe H, Kimata K, Line S, Strong D, Gao LY, Kozak CA, Yamada Y. Mouse cartilage matrix deficiency (cmd) caused by a 7 bp deletion in the aggrecan gene. Nat Genet 1994; 7(2):154-7.
80. Kimata K, Barrach HJ, Brown KS, Pennypacker JP. Absence of proteoglycan core protein in cartilage from the cmd/cmd (cartilage matrix deficiency) mouse. J Biol Chem 1981; 256(13):6961-8.
81. Domowicz MS, Pirok EW, 3rd, Novak TE, Schwartz NB. Role of the C-terminal G3 domain in sorting and secretion of aggrecan core protein and ubiquitin-mediated degradation of accumulated mutant precursors. J Biol Chem 2000; 275(45):35098-105.
82. Chen L, Wu Y, Lee V, Kiani C, Adams ME, Yao Y, Yang BB. The folded modules of aggrecan G3 domain exert two separable functions in glycosaminoglycan modification and product secretion. J Biol Chem 2002; 277(4):2657-65.
83. Wu Y, Zhang Y, Cao L, Chen L, Lee V, Zheng PS, Kiani C, Adams ME, Ang LC, Paiwand F, Yang BB. Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J Biol Chem 2001; 276(17):14178-86.
84. 1-Integrin mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol chem 2001; 277 JBC paper in press, published on January 22, 2002 as Manuscript M110748200.